{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:28:01Z","timestamp":1792294081436,"version":"4.4.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Numerous candidate vaccines against cytomegalovirus (CMV) infection and disease are in development. Whereas the previous article [1] provides background and opinions about the issues relating to vaccination, this article provides specifics about the vaccines in active development, as reported at a National Institutes of Health-sponsored meeting in Bethesda on September 4\u20136, 2018. Here, vaccine developers provide synopses of their candidate vaccines to immunize women to protect against congenital CMV disease and to prevent the consequences of CMV disease in recipients of transplanted organs or hematopoietic stem calls. The projects are presented here roughly in the descending order of their stage of development in the opinion of the first author.<\/jats:p>","DOI":"10.1093\/infdis\/jiz447","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T19:25:25Z","timestamp":1567193125000},"page":"S113-S122","source":"Crossref","is-referenced-by-count":115,"title":["The Status of Vaccine Development Against the Human Cytomegalovirus"],"prefix":"10.1093","volume":"221","author":[{"given":"Stanley A","family":"Plotkin","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Pennsylvania, Vaxconsult, Doylestown, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Wang","sequence":"first","affiliation":[{"name":"Merck & Co., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel","family":"Oualim","sequence":"first","affiliation":[{"name":"Sanofi-Pasteur, Swiftwater, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don J","family":"Diamond","sequence":"first","affiliation":[{"name":"City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille N","family":"Kotton","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mossman","sequence":"first","affiliation":[{"name":"GlaxoSmithKline Vaccines, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carfi","sequence":"first","affiliation":[{"name":"Moderna Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Anderson","sequence":"first","affiliation":[{"name":"VBI Vaccines, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R","family":"Dormitzer","sequence":"first","affiliation":[{"name":"Pfizer Vaccines, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"2020030507500319300_CIT0001","volume-title":"Can Infection by the","author":"Plotkin SA","year":"2019"},{"key":"2020030507500319300_CIT0002","doi-asserted-by":"crossref","first-page":"362ra145","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Wang","year":"2016","journal-title":"Sci Transl Med"},{"key":"2020030507500319300_CIT0003","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/infdis\/jiz141","article-title":"Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects","volume":"220","author":"Adler","year":"2019","journal-title":"J Infect Dis"},{"key":"2020030507500319300_CIT0004","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02033-16","article-title":"Neutralization of diverse human cytomegalovirus strains conferred by antibodies targeting viral gH\/gL\/pUL128-131 pentameric complex","volume":"91","author":"Ha","year":"2017","journal-title":"J Virol"},{"key":"2020030507500319300_CIT0005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0264-410X(90)90135-9","article-title":"Isolated gA\/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers","volume":"8","author":"Gonczol","year":"1990","journal-title":"Vaccine"},{"key":"2020030507500319300_CIT0006","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/315022","article-title":"A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant","volume":"180","author":"Pass","year":"1999","journal-title":"J Infect Dis"},{"key":"2020030507500319300_CIT0007","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94002","article-title":"Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys","volume":"2","author":"Nelson","year":"2017","journal-title":"JCI Insight"},{"key":"2020030507500319300_CIT0008","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"2020030507500319300_CIT0009","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"2020030507500319300_CIT0010","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/infdis\/jir138","article-title":"Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women","volume":"203","author":"Sabbaj","year":"2011","journal-title":"J Infect Dis"},{"key":"2020030507500319300_CIT0011","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"2020030507500319300_CIT0012","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood-2016-07-729756","article-title":"MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults","volume":"129","author":"La Rosa","year":"2017","journal-title":"Blood"},{"key":"2020030507500319300_CIT0013","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2008.04.034","article-title":"A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector","volume":"377","author":"Wang","year":"2008","journal-title":"Virology"},{"key":"2020030507500319300_CIT0014","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.vaccine.2009.11.056","article-title":"Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines","volume":"28","author":"Wang","year":"2010","journal-title":"Vaccine"},{"key":"2020030507500319300_CIT0015","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2003-10-3469","article-title":"Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells","volume":"104","author":"Wang","year":"2004","journal-title":"Blood"},{"key":"2020030507500319300_CIT0016","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01012-18","article-title":"Multiantigenic modified vaccinia virus ankara vaccine vectors to elicit potent humoral and cellular immune reponses against human cytomegalovirus in mice","volume":"92","author":"Chiuppesi","year":"2018","journal-title":"J Virol"},{"key":"2020030507500319300_CIT0017","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14760584.2018.1526085","article-title":"A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection","volume":"17","author":"Diamond","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"2020030507500319300_CIT0018","article-title":"OS6-1 \u2013 multi-antigen vaccine (Triplex) based on attenuated poxvirus prevents cytomegalovirus viremia in a multi-center placebo-controlled, double-blinded, randomized phase 2 clinical trial in allogeneic HCT recipients [abstract]","author":"Aldoss","year":"2019"},{"key":"2020030507500319300_CIT0018a","doi-asserted-by":"crossref","DOI":"10.7326\/M19-2511","article-title":"Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial [Epub ahead of print February 11, 2020]","author":"Aldoss","year":"2020","journal-title":"Ann Intern Med"},{"key":"2020030507500319300_CIT0019","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1365-2567.2002.01396.x","article-title":"Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses","volume":"106","author":"BenMohamed","year":"2002","journal-title":"Immunology"},{"key":"2020030507500319300_CIT0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0198-8859(00)00139-7","article-title":"Induction of CTL response by a minimal epitope vaccine in HLA A*0201\/DR1 transgenic mice: dependence on HLA class II restricted T(H) response","volume":"61","author":"BenMohamed","year":"2000","journal-title":"Hum Immunol"},{"key":"2020030507500319300_CIT0021","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood-2002-03-0926","article-title":"Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice","volume":"100","author":"La Rosa","year":"2002","journal-title":"Blood"},{"key":"2020030507500319300_CIT0022","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1182\/blood.V90.5.1751","article-title":"Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection","volume":"90","author":"Diamond","year":"1997","journal-title":"Blood"},{"key":"2020030507500319300_CIT0023","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s002510000271","article-title":"Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes","volume":"52","author":"Longmate","year":"2001","journal-title":"Immunogenetics"},{"key":"2020030507500319300_CIT0024","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/infdis\/jis107","article-title":"Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant","volume":"205","author":"La Rosa","year":"2012","journal-title":"J Infect Dis"},{"key":"2020030507500319300_CIT0025","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3026(15)00246-X","article-title":"Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial","volume":"3","author":"Nakamura","year":"2016","journal-title":"Lancet Haematol"},{"key":"2020030507500319300_CIT0026","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bbmt.2018.12.070","article-title":"Rapid acquisition of cytomegalovirus-specific T cells with a differentiated phenotype, in nonviremic hematopoietic stem transplant recipients vaccinated with CMVPepVax","volume":"25","author":"La Rosa","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020030507500319300_CIT0027","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat Med"},{"key":"2020030507500319300_CIT0028","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00300-16","article-title":"Additive protection against congenital cytomegalovirus conferred by combined glycoprotein B\/pp65 vaccination using a lymphocytic choriomeningitis virus vector","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2020030507500319300_CIT0029","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/vaccines1040398","article-title":"Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial","volume":"1","author":"Smith","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"2020030507500319300_CIT0030","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am J Transplant"},{"key":"2020030507500319300_CIT0031","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020030507500319300_CIT0032","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J Virol"},{"key":"2020030507500319300_CIT0033","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"2020030507500319300_CIT0034","doi-asserted-by":"crossref","first-page":"e59863","DOI":"10.1371\/journal.pone.0059863","article-title":"Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH\/gL\/pUL128-130-131 complex during primary infection","volume":"8","author":"Lilleri","year":"2013","journal-title":"PLoS One"},{"key":"2020030507500319300_CIT0035","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aan1457","article-title":"Structural basis for potent antibody-mediated neutralization of human cytomegalovirus","volume":"2","author":"Chandramouli","year":"2017","journal-title":"Sci Immunol"},{"key":"2020030507500319300_CIT0036","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"2020030507500319300_CIT0037","doi-asserted-by":"crossref","first-page":"e1002172","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies","volume":"7","author":"P\u00f6tzsch","year":"2011","journal-title":"PLoS Pathog"},{"key":"2020030507500319300_CIT0038","doi-asserted-by":"crossref","first-page":"e1005227","DOI":"10.1371\/journal.ppat.1005227","article-title":"Crystal structure of the human cytomegalovirus glycoprotein B","volume":"11","author":"Burke","year":"2015","journal-title":"PLoS Pathog"},{"key":"2020030507500319300_CIT0039","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1399-3062.2010.00563.x","article-title":"Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors","volume":"13","author":"Ishibashi","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"2020030507500319300_CIT0040","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/infdis\/jiy102","article-title":"Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: anti-AD2 levels correlate with protection from viremia","volume":"217","author":"Baraniak","year":"2018","journal-title":"J Infect Dis"},{"key":"2020030507500319300_CIT0041","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.vaccine.2007.10.048","article-title":"Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines","volume":"26","author":"Axelsson","year":"2007","journal-title":"Vaccine"},{"key":"2020030507500319300_CIT0042","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2014.03.015","article-title":"A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?","volume":"60","author":"Ohlin","year":"2014","journal-title":"Mol Immunol"},{"key":"2020030507500319300_CIT0043","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.vaccine.2014.05.004","article-title":"Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"key":"2020030507500319300_CIT0044","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1128\/JVI.74.13.6132-6146.2000","article-title":"Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression","volume":"74","author":"Pepperl","year":"2000","journal-title":"J Virol"},{"key":"2020030507500319300_CIT0045","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00430-016-0472-z","article-title":"Prospects of a vaccine for the prevention of congenital cytomegalovirus disease","volume":"205","author":"Plachter","year":"2016","journal-title":"Med Microbiol Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/Supplement_1\/S113\/32791277\/jiz447.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/Supplement_1\/S113\/32791277\/jiz447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T12:50:22Z","timestamp":1583412622000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/Supplement_1\/S113\/5781893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":46,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,3,5]]},"published-print":{"date-parts":[[2020,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz447","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,15]]},"published":{"date-parts":[[2020,3,5]]}}}